
My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.
Education and Training
- Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
- Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
- M.D., University Missouri Kansas City, 1992
Grants
- Gilead 384-1943
- Gilead 384-1944
- Madrigal MGL-3196-11
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
- ARMOR
- Celgene CC-90001 NASH-001
- NovoNordisk 4492
- Duke CTSA (KL2)
- Duke CTSA (TL1)
- Target-NASH
- Intercept 747-303
- Genentech GC41003
- Durect DUR-928
- FALCON 1
- FALCON 2
- Inventiva IVA337
- NGM282 18-0108
- Genfit GFT505-315-1 NASH
- STAMP - STudy of AMP Kinase Activator
- Novartis LJC242A2201J
- Intercept 747-304
- Galectin GI-026
- Enyo EYP001-202
- Allergan 301-002
- Allergan 201-002
- Progenity PRO-121-NAFLD
- Enanta EDP 305-101
- Conatus IDN 6556-17
- Gilead 454-4378
- Boehringer BI 1467335
- Gilead 384-1497
- Genetic and Epigenetic Markers of Progressive Nonalcoholic Fatty Liver Disease
- Conatus IDN 6556-14
- TOBIRA 652-2-203